Anthony Walsh - Sumitomo Dainippon Insider

DPM -- Germany Stock  

EUR 18.17  0.00  0.00%

Independent Director
Mr. Anthony P. Walsh is an Independent Director of Dundee Precious Metals Inc. Mr. Walsh has over 25 years experience in the field of exploration, mining and development. Most recently, Mr. Walsh was President and CEO of Sabina Gold Silver Corporationration from 2008 to 2011, prior to which he served as President and CEO of Miramar Mining Corporationrationration from 1995 to 2007, Senior Vice President and Chief Financial Officer of a computer leasing company from 1993 to 1995 and Chief Financial Officer and Senior Vice President, Finance of International Corona Mines Ltd., a major North American gold producer from 1989 to 1992. Mr. Walsh also serves on the board of directors of several publiclytraded exploration and development companies. Mr. Walsh graduated from Queens University in 1973 and became a member of The Canadian Institute of Chartered Accountants in 1976.
Age: 64  Director Since 2012      
81 6 6203 5321  http://www.ds-pharma.com

Anthony Walsh Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 6.45 % which means that it generated profit of $6.45 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 11.7 % meaning that it generated $11.7 on every $100 dollars invested by stockholders.
The company has accumulated 450.43 M in total debt with debt to equity ratio (D/E) of 10.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sumitomo Dainippon Pharma Co Ltd has Current Ratio of 1.63 which is within standard range for the sector.

Similar Executives

Entity Summary

Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients, food additives, veterinary medicines, diagnostics, and others. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited. Sumitomo Dainippon operates under Drug Manufacturers - Specialty Generic classification in Germany and traded on Frankfurt Stock Exchange. It employs 6268 people.Sumitomo Dainippon Pharma Co Ltd (DPM) is traded on Frankfurt Stock Exchange in Germany. It is located in 6-8 Doshomachi 2-chome and employs 6,268 people.

Sumitomo Dainippon P Leadership Team

Peter Nixon, Director
Jonathan Goodman, CEO, MBA
Richard Gosse, President
Colin McAnuff, Executive
John Lindsay, President
Mark Crawley, President
Peter Gillin, Director
MarieAnne Tawil, Director, MBA
Richard Howes, President
Hume Kyle, President
Anthony Walsh, Director
Garth MacRae, Director
Zebra Kasete, President, MBA
Juanita Montalvo, Director
David Rae, President
Donald Young, Director
Michael Dorfman, President
Lori Beak, President
Jeremy Kinsman, Director, MBA
Brent Johnson, President
Paul Proulx, President
Nikolay Hristov, President
Murray John, Director, MBA
Hratch Jabrayan, President

Stock Performance Indicators

Current Sentiment - DPM

Sumitomo Dainippon P Investor Sentiment
Macroaxis portfolio users are insensible in their opinion about investing in Sumitomo Dainippon Pharma Co Ltd. What is your outlook on investing in Sumitomo Dainippon Pharma Co Ltd? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Sumitomo Dainippon and Apple. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.